Oppenheimer Begins Coverage on Millendo Therapeutics (NASDAQ:MLND)

Oppenheimer assumed coverage on shares of Millendo Therapeutics (NASDAQ:MLND) in a research note released on Tuesday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $26.00 price objective on the stock. Oppenheimer also issued estimates for Millendo Therapeutics’ Q2 2019 earnings at ($0.83) EPS, Q3 2019 earnings at ($0.86) EPS, Q4 2019 earnings at ($0.87) EPS, FY2019 earnings at ($3.33) EPS, FY2020 earnings at ($4.11) EPS, FY2021 earnings at ($5.41) EPS, FY2022 earnings at ($5.93) EPS and FY2023 earnings at ($4.66) EPS.

Several other analysts have also recently weighed in on the company. Citigroup set a $12.00 price target on Controladora Vuela Co Avcn SA CV and gave the stock a buy rating in a report on Monday. Zacks Investment Research raised Golub Capital BDC from a hold rating to a buy rating and set a $20.00 price target for the company in a report on Tuesday. Finally, ValuEngine cut Welbilt from a hold rating to a sell rating in a report on Wednesday, June 12th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $24.38.

NASDAQ:MLND traded up $0.05 during mid-day trading on Tuesday, hitting $10.70. 4,660 shares of the stock were exchanged, compared to its average volume of 106,299. The stock has a market cap of $141.89 million, a PE ratio of -0.61 and a beta of 2.61. The stock’s 50-day moving average price is $12.68. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83. Millendo Therapeutics has a fifty-two week low of $6.77 and a fifty-two week high of $17.34.

Millendo Therapeutics (NASDAQ:MLND) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.08). As a group, equities analysts anticipate that Millendo Therapeutics will post -3.27 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of MLND. Geode Capital Management LLC bought a new position in Millendo Therapeutics during the 4th quarter worth $113,000. BlackRock Inc. bought a new position in Millendo Therapeutics during the 4th quarter worth $203,000. Worth Venture Partners LLC bought a new position in Millendo Therapeutics during the 4th quarter worth $206,000. Private Advisors LLC increased its stake in Millendo Therapeutics by 9.1% during the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after acquiring an additional 1,279 shares during the period. Finally, Tibra Equities Europe Ltd bought a new position in Millendo Therapeutics during the 1st quarter worth $303,000. Hedge funds and other institutional investors own 44.07% of the company’s stock.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

See Also: What is the Quick Ratio?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.